23230-39-9

Basic information

• Product Name: 1-[(DIMETHYLAMINO)METHYL]IMIDAZOLE
• Synonyms: 1-[(DIMETHYLAMINO)METHYL]IMIDAZOLE;Imidazol-1-ylmethyl-dimethyl-amine;1-(1H-IMidazol-1-yl)-N,N-diMethylMethanaMine;1-Imidazol-1-yl-N,N-dimethyl-methanamine
• CAS NO: 23230-39-9
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.17164
• Mol File: 23230-39-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 226.2°C at 760 mmHg
• Flash Point: 90.6°C
• Appearance: /
• Density: 1g/cm³
• Vapor Pressure: 0.0831mmHg at 25°C
• Refractive Index: 1.524
• CAS DataBase Reference: 1-[(DIMETHYLAMINO)METHYL]IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(DIMETHYLAMINO)METHYL]IMIDAZOLE(23230-39-9)
• EPA Substance Registry System: 1-[(DIMETHYLAMINO)METHYL]IMIDAZOLE(23230-39-9)

Safety Data

• Hazardous Substances Data: 23230-39-9(Hazardous Substances Data)

Usage

Molecular weight

150.18 g/mol
The mass of one mole of the compound, expressed in grams per mole.

Heterocyclic organic compound

Imidazole derivative
A type of organic compound containing a ring of atoms with at least one heteroatom (non-carbon atom), in this case, nitrogen.

Structure

Imidazole ring with a dimethylaminoethyl group attached to one of the nitrogen atoms
The specific arrangement of atoms in the compound, with a five-membered imidazole ring and a dimethylaminoethyl side chain.

Application

Medicinal and pharmaceutical research
The compound is used in the development and study of new drugs and pharmaceuticals.

Role

Ligand in the synthesis of coordination compounds
Acts as a binding agent to form complexes with metal ions, which can be useful in various applications.

Potential applications

Organic chemistry, biochemistry, and drug development
The compound may have uses in these scientific fields due to its unique structure and properties.

Studied properties

Anti-cancer and anti-microbial
The compound has been investigated for its potential to combat cancer and inhibit the growth of microorganisms.

InChI:InChI=1/C6H11N3/c1-8(2)6-9-4-3-7-5-9/h3-5H,6H2,1-2H3

Upstream product

• 288-32-4 1H-imidazole 
• 50-00-0 formaldehyd 
• 506-59-2 N,N-dimethylammonium chloride 
• 124-40-3 dimethyl amine 
• 51-80-9 bis-(dimethylamino)methane 
• 584-08-7 potassium carbonate 

Downstream Products

• 117024-16-5 α-(imidazol-2-yl)-4-methylbenzyl alcohol 
• 5228-76-2 (imidazol-2-yl)diphenylmethanol 
• 116997-22-9 (1H-imidazol-2-yl)(p-tolyl)methanone 
• 173170-15-5 2,3,4,6-tetra-O-benzyl-1-C-(1H-imidazol-2-yl)-α-D-glucopyranose 
• 61491-92-7 2-(2-methyl propyl)-imidazole 
• 14700-62-0 2-benzyl-1H-imidazole 
• 1254160-53-6 [2-(2,3-difluoro-6-methoxy-phenyl)-pyridin-4-yl]-(1H-imidazol-2-yl)-methanone 

Relevant articles and documents

Design, synthesis and biological evaluation of novel benzoylimidazole derivatives as RAF and histone deacetylases dual inhibitors

In recent studies, combinations of histone deacetylases (HDACs) inhibitor with kinase inhibitor showed additive and synergistic effects. BRafV600E as an attractive target in many diseases treatments has been studied extensively. Herein, we pres

IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES

The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists

Structure-activity studies around the 4-position of 2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists suggest that there is a large lipophilic cavity in the rat CRF receptor, which can accommodate a wide variety of substituents at this position in contrast to the steric constraints observed for other positions on the 2-anilinopyrimidine core. The chemical syntheses and biological activities of 2-anilinopyrimidine CRF antagonists with carbon-linked substituents at the 4-position are reported. Significant improvements in rat pharmacokinetic parameters were achieved relative to those for the lead structure. While the lead compound 1 (rCRF K(i) = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (ip) or oral (po) dosing, compounds 3-3 (rCRF K(i) = 16 nM) and 3-4 (rCRF K(i) = 59 nM) gave high rat plasma levels at 30 mg/kg (ip, po) (C(max) = 1389 nM and 8581 nM (ip) respectively; C(max) = 113 nM and 988 nM (po), respectively). Furthermore 3-3 and 3-4 had superior bioavailabilities at these doses (59 and 46% (ip), respectively; 2 and 10% (po), respectively). (C) 1999 DuPont Pharmaceuticals Company.